Chemomab Therapeutics to Attend Scientific Conferences - May 17, 2024
May 17, 2024 – Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a biotechnology company focused on developing treatments for fibro-inflammatory diseases, has announced its participation in upcoming scientific conferences. The company will present new research at both the Gordon Research Conference on Chemotactic Cytokines and EASL 2024, the Annual Congress of the European Association for the Study of the Liver.
At these conferences, Chemomab will present a variety of findings related to their research on the soluble protein target CCL24 and their proprietary CCL24 neutralizing antibody, CM-101. These presentations will include insights from preclinical studies on the role of CCL24 in fibro-inflammatory diseases and translational research that supports the clinical development of CM-101 for treating primary sclerosing cholangitis, a serious fibrotic liver condition. The detailed information from these presentations will be released post embargo.
The Gordon Research Conference on Chemotactic Cytokines will take place in Portland, Maine, from June 2-7, 2024. Chemomab will present a poster titled "Attenuating liver fibrosis and inflammation: blocking CCL24 inhibits recruitment of hepatic stellate cells, monocytes, and neutrophils and modulates hepatic stellate cell activation." The presentation will be delivered by Prof. Amnon Peled from Hadassah University Hospital and Hebrew University.
At the EASL Congress 2024 in Milan, Italy, from June 5-8, 2024, Chemomab's team will present several posters:
- On June 6, from 8:30 to 18:00 CEST, Dr. Revital Aricha, Vice President of Translational Science at Chemomab, will present a poster on an ex-vivo translational assay of hepatic stellate cells using patient-derived serum, which characterizes the anti-fibrotic activity of CM-101. This session will focus on fibrosis and stellate cell biology.
- Also on June 6, from 8:30 to 17:00 CEST, Dr. Ilan Vaknin, Vice President of R&D at Chemomab, will present a poster on the machine learning-driven identification of serum protein signatures for primary sclerosing cholangitis and an enhanced liver fibrosis score. This session is part of the Immune-mediated and cholestatic: Experimental and pathophysiology segment.
- On June 7, from 12:25 to 13:45 CEST, Dr. Ilan Vaknin will again present, this time during a poster tour session on fibrosis and stellate cell biology. The focus will be on an ex-vivo translational assay of hepatic stellate cells using patient-derived serum and the anti-fibrotic activity of CM-101.
Additionally, Chemomab's Corporate Development team will attend the BIO International Convention’s One-on-One Partnering™ event in San Diego from June 3-6, 2024. This event offers registered attendees the opportunity to schedule meetings with Chemomab representatives.
Chemomab Therapeutics Ltd. is a biotechnology firm advancing therapies for fibro-inflammatory diseases. Their lead product, CM-101, is a monoclonal antibody targeting CCL24, a protein that promotes fibrosis and inflammation. CM-101 has shown promise in treating various severe fibro-inflammatory conditions, with positive results from multiple clinical trials, including a Phase 2a trial for liver fibrosis in NASH patients and a study on severe lung injury. A Phase 2 trial for primary sclerosing cholangitis has completed enrollment, with results expected in mid-2024. Chemomab’s program for systemic sclerosis is also ready for Phase 2 trials in the U.S.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
